Neuroprotective effects of 3α-acetoxyeudesma-1,4(15),11(13)-trien-12, 6α-olide against dopamine-induced apoptosis in the human neuroblastoma SH-SY5Y cell line

Neurochemical Research

Volumn 36, Issue 11, 2011, Pages 1991-2001

  Koo, Uk ^a   Nam, Kung Woo ^b   Ham, Ahrom ^a   Lyu, Dahyun ^a   Kim, Bora ^a   Lee, Sung Jin ^c   Kim, Kyeong Ho ^c   Oh, Ki Bong ^d   Mar, Woongchon ^a   Shin, Jongheon ^a  

^a Seoul National University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

synuclein; 11(13) trien 12; 3 acetoxyeudesma 1; 4(15); 6 olide; Apoptosis; Dopamine; Quinoprotein; Tyrosinase activity

Indexed keywords

3ALPHA ACETOXYEUDESMA 1,4(15),11(13) TRIEN 12,6ALPHA OLIDE; ALPHA SYNUCLEIN; CASPASE 3; DOPAMINE; MONOPHENOL MONOOXYGENASE; NEUROPROTECTIVE AGENT; PLANT EXTRACT; PROTEIN BCL 2; PROTEIN P57; RESVERATROL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; LAURUS NOBILIS; NEUROBLASTOMA CELL; NEUROPROTECTION; PHYTOCHEMISTRY; PLANT LEAF; PRIORITY JOURNAL;

ALPHA-SYNUCLEIN; ANTIOXIDANTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DOPAMINE; HUMANS; LAURUS; MONOPHENOL MONOOXYGENASE; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SESQUITERPENES, EUDESMANE;

LAURUS NOBILIS;

EID: 80054994567     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0523-1     Document Type: Article

References (50)

1. AM Bonnet JL Houeto 1999 Pathophysiology of Parkinson's disease Biomed Pharmacother 53 117 121 10349507 10.1016/S0753-3322(99)80076-6 1:STN:280:DyaK1M3nvFWhtg%3D%3D (Pubitemid 29507873)
2. CW Olanow WG Tatton 1999 Etiology and pathogenesis of Parkinson's disease Annu Rev Neurosci 22 123 144 10202534 10.1146/annurev.neuro.22.1.123 1:CAS:528:DyaK1MXhvFemsro%3D (Pubitemid 29144883)
3. CW Olanow 1993 A radical hypothesis for neurodegeneration Trends Neurosci 16 439 444 7507613 10.1016/0166-2236(93)90070-3 1:CAS:528:DyaK2cXltFKqsw%3D%3D (Pubitemid 23313517)
4. E Junn MM Mouradian 2001 Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases J Neurochem 78 374 383 11461973 10.1046/j.1471-4159. 2001.00425.x 1:CAS:528:DC%2BD3MXlsVeitrg%3D (Pubitemid 32664419)
5. DG Graham 1978 Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol Pharmacol 14 633 643 98706 1:CAS:528:DyaE1cXlsF2is7w%3D (Pubitemid 8402469)
6. G Cohen RE Heikkila 1974 The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents J Biol Chem 249 2447 2452 4362682 1:CAS:528:DyaE2cXltVShtbg%3D
7. TG Hastings 1995 Enzymatic oxidation of dopamine: the role of prostaglandin H synthase J Neurochem 64 919 924 7830086 10.1046/j.1471-4159. 1995.64020919.x 1:CAS:528:DyaK2MXjtFymtL8%3D
8. B Halliwell 1992 Reactive oxygen species and the central nervous system J Neurochem 59 1609 1623 1402908 10.1111/j.1471-4159.1992.tb10990.x 1:CAS:528:DyaK38XmsVKlsbk%3D
9. B Drukarch FL van Muiswinkel 2000 Drug treatment of Parkinson's disease. Time for phase II Biochem Pharmacol 59 1023 1031 10704931 10.1016/S0006-2952(99) 00340-8 1:CAS:528:DC%2BD3cXhsFGqtrc%3D (Pubitemid 30110494)
10. JD Elsworth RH Roth 1997 Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease Exp Neurol 144 4 9 9126143 10.1006/exnr.1996.6379 1:CAS:528:DyaK2sXis1Gks7o%3D (Pubitemid 27149594)
11. E Karg G Odh A Wittbjer, et al. 1993 Hydrogen peroxide as an inducer of elevated tyrosinase level in melanoma cells J Invest Dermatol 100 209S 213S 8433009 10.1038/jid.1993.37 1:CAS:528:DyaK3sXhs1Kgtr8%3D (Pubitemid 23051700)
12. D Sulzer L Zecca 2000 Intraneuronal dopamine-quinone synthesis: a review Neurotox Res 1 181 195 12835101 10.1007/BF03033289 1:CAS:528: DC%2BD3cXjsFCls7w%3D
13. I Tessari M Bisaglia F Valle, et al. 2008 The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease J Biol Chem 283 16808 16817 18390556 10.1074/jbc.M709014200 1:CAS:528:DC%2BD1cXmslOitrw%3D
14. Y Masamoto H Ando Y Murata, et al. 2003 Mushrrom tyrosinase inhibitory activity of esculetin isolated from seeds of Euphorbia lathyris L Biosci Biotechnol Biochem 67 631 634 12723615 10.1271/bbb.67.631 1:CAS:528: DC%2BD3sXivFKqu7s%3D (Pubitemid 39251963)
15. S Wada H Ichikawa K Tastsumi 1995 Removal of phenols and aromatic amines from wastewater by a combination treatment with tyrosinase and a coagulant Biotechnol Bioeng 45 304 309 18623183 10.1002/bit.260450404 1:CAS:528: DyaK2MXktVKns78%3D
16. YJ Mun SW Lee HW Jeong, et al. 2004 Inhibitory effect of miconazole on melanogenesis Biol Pharm Bull 27 806 809 15187422 10.1248/bpb.27.806 1:CAS:528:DC%2BD2cXltFKqtrY%3D (Pubitemid 41701793)
17. D Huang B Ou M Hampsch-Woodill JA Flanagan, et al. 2002 Development and validation of oxygen radical absorbance capacity assay for lipophilic antioxidants using randomly methylated beta-cyclodextrin as the solubility enhancer J Agric Food Chem 50 1815 1821 11902917 10.1021/jf0113732 1:CAS:528:DC%2BD38XhtVKitL0%3D (Pubitemid 34259972)
18. DA Bass JW Parce LR Dechatelet, et al. 1983 Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation J Immunol 130 1910 1917 6833755 1:CAS:528:DyaL3sXhslOgu78%3D (Pubitemid 13091657)
19. Y Ikeda S Tsuji A Satoh M Ishikura T Shirasawa T Shimizu 2008 Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells J Neurochem 107 1730 1740 19014378 10.1111/j.1471-4159.2008.05743.x 1:CAS:528:DC%2BD1MXis1Sqsg%3D%3D
20. CS Lee ES Han JH Song KY Kim 2004 Inhibition of SIN-1-induced change in mitochondrial membrane permeability in PC12 cells by dopamine Neurochem Res 29 1371 1379 15202767 10.1023/B:NERE.0000026399.14754.a0 1:CAS:528: DC%2BD2cXjs1Kisb8%3D (Pubitemid 39011322)
21. SH Merchant NJ Gonchoroff RE Hutchison 2001 Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes Cytometry 46 28 32 11241504 10.1002/1097- 0320(20010215)46:1<28::AID-CYTO1034>3.0.CO;2-H 1:STN:280: DC%2BD3M3jsVOgsw%3D%3D (Pubitemid 32216735)
22. MA Paz R Fluckiger A Boak, et al. 1991 Specific detection of quinoproteins by redox-cycling staining J Biol Chem 266 689 692 1702437 1:CAS:528:DyaK3MXpslWhsw%3D%3D (Pubitemid 21907168)
23. M Asanuma I Miyazaki N Ogawa 2003 Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease Neurotox Res 5 165 176 12835121 10.1007/BF03033137
24. DW Nicholson A Ali NA Thornberry JP Vaillancourt CK Ding M Gallant Y Gareau PR Griffin M Labelle YA Lazebnik NA Munday SM Raju ME Smulson T-T Yamin VL Yu DK Miller 1995 Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 376 37 43 7596430 10.1038/376037a0 1:CAS:528:DyaK2MXmvVGqu7k%3D
25. EC Hirsch 1993 Does oxidative stress participate in nerve cell death in Parkinson's disease Eur Neurol 33 52 59 8375433 10.1159/000118538 (Pubitemid 23235377)
26. P Jenner 1998 Oxidative mechanisms in nigral cell death in Parkinson's disease Mov Disord 13 24 34 9613715
27. LA Gomez Sarosi MS Rieber M Rieber 2003 Hydrogen peroxide increases a 55-kDa tyrosinase concomitantly with induction of p53-dependent p21 waf1 expression and a greater Bax/Bcl-2 ratio in pigmented melanoma Biochem Biophys Res Commun 312 355 359 14637145 10.1016/j.bbrc.2003.10.133 (Pubitemid 37445180)
28. ZD Zhou TM Lim 2009 Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones Free Radic Res 43 417 430 19291591 10.1080/10715760902801533 1:CAS:528:DC%2BD1MXjvFOntrs%3D
29. M Baranyi E Milusheva ES Vizi B Sperlagh 2006 Chromatographic analysis of dopamine metabolism in a Parkinsonian model J Chromatogr A 1120 13 20 16580006 10.1016/j.chroma.2006.03.018 1:CAS:528:DC%2BD28XmtV2qtrY%3D (Pubitemid 43866771)
30. JD Adams Jr IN Odunze 1991 Oxygen free radicals and Parkinson's disease Free Radic Biol Med 10 161 169 2016074 10.1016/0891-5849(91)90009-R 1:CAS:528:DyaK3MXkvFSjsr8%3D (Pubitemid 121003223)
31. LJ Hsu Y Sagara A Arroyo, et al. 2000 α-synuclein promotes mitochondrial deficit and oxidative stress Am J Pathol 157 401 410 10934145 10.1016/S0002-9440(10)64553-1 1:CAS:528:DC%2BD3cXlvFyru7k%3D (Pubitemid 30627559)
32. C Gomez-Santos I Ferrer AF Santidrian, et al. 2003 Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells J Neurosci Res 73 341 350 12868068 10.1002/jnr.10663 1:CAS:528:DC%2BD3sXmt1Gjsrk%3D (Pubitemid 36918098)
33. Y Xu AH Stokes R Roskoski, et al. 1998 Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase J Neurosci Res 54 691 697 9843160 10.1002/(SICI)1097-4547(19981201)54:5<691::AID- JNR14>3.0.CO;2-F 1:CAS:528:DyaK1cXnslOgsL8%3D (Pubitemid 28546072)
34. E Greggio E Bergantino D Carter, et al. 2005 Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease J Neurochem 93 246 256 15773923 10.1111/j.1471-4159.2005.03019.x 1:CAS:528:DC%2BD2MXjtFCgtLY%3D (Pubitemid 40463533)
35. T Hasegawa A Treis N Patenge, et al. 2008 Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways J Neurochem 105 1700 1715 18248610 10.1111/j.1471-4159. 2008.05277.x 1:CAS:528:DC%2BD1cXntVCksbY%3D (Pubitemid 351678502)
36. M Miranda D Botti 1983 Harding-passey mouse-melanoma tyrosinase inactivation by reaction products and activation by L-epinephrine Gen Pharmacol 14 231 237 6404691 10.1016/0306-3623(83)90002-2 1:CAS:528:DyaL3sXhslGntLg%3D (Pubitemid 13142283)
37. D Sulzer 2007 Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease Trends Neurosci 30 244 250 17418429 10.1016/j.tins.2007.03. 009 1:CAS:528:DC%2BD2sXkslent7g%3D (Pubitemid 46667168)
38. P Burnard JY Berthon 2000 Resveratrol:an original mechanism on tyrosinase inhibition Int J Cosmet Sci 22 219 226 10.1046/j.1467-2494.2000.00019.x (Pubitemid 30389328)
39. K Ohguchi T Tanaka T Ito M Iinuma K Matsumoto Y Akao Y Nozawa 2003 Inhibitory effects of resveratrol derivatives from dipterocarpaceae plants on tyrosinase activity Biosci Biotechnol Biochem 67 1587 1589 12913307 10.1271/bbb.67.1587 1:CAS:528:DC%2BD3sXmtFeksrk%3D (Pubitemid 39251801)
40. MK Lee SJ Kang M Poncz KJ Song KS Park 2007 Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine Exp Mol Med 39 376 384 17603292 1:CAS:528:DC%2BD2sXnvVWls7Y%3D (Pubitemid 47037629)
41. F Jin Q Wu YF Lu QH Gong JS Shi 2008 Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats Eur J Parmacol 600 78 82 10.1016/j.ejphar.2008.10.005 1:CAS:528:DC%2BD1cXhtlyltLvJ
42. J Blanchet F Longpre G Bureau M Morissette T DiPaolo G Bronchti MG Martinoli 2008 Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice Prog Neuropsychopharmacol Biol Psychiatry 32 1243 1250 18471948 10.1016/j.pnpbp.2008.03.024 1:CAS:528:DC%2BD1cXnsF2lu78%3D
43. B Fornstedt E Rosengren A Carlsson 1986 Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species Neuropharmacology 25 451 454 3086766 10.1016/0028-3908(86) 90242-X 1:CAS:528:DyaL28XktlKisL0%3D (Pubitemid 16109584)
44. DM Kuhn RE Arthur Jr DM Thomas LA Elferink 1999 Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease J Neurochem 73 1309 1317 10461926 10.1046/j.1471-4159.1999.0731309.x 1:CAS:528:DyaK1MXlsVOiurw%3D (Pubitemid 29395493)
45. MJ LaVoie BL Ostaszewski A Weihofen MG Schlossmacher DJ Selkoe 2005 Dopamine covalently modifies and functionally inactivates parkin Nat Med 11 1214 1221 16227987 10.1038/nm1314 1:CAS:528:DC%2BD2MXhtFOhsLvP (Pubitemid 43093669)
46. RE Whitehead JV Ferrer JA Javitch JB Justice 2001 Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter J Neurochem 76 1242 1251 11181843 10.1046/j.1471-4159.2001.00125.x 1:CAS:528:DC%2BD3MXhs12nsrg%3D (Pubitemid 32167397)
47. J Xu SY Kao FJ Lee W Song LW Jin BA Yankner 2002 Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nat Med 8 600 606 12042811 10.1038/nm0602-600 1:CAS:528:DC%2BD38XktVyit7w%3D (Pubitemid 34633438)
48. DF Clayton JM George 1998 The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease Trends Neurosci 21 249 254 9641537 10.1016/S0166-2236(97)01213-7 1:CAS:528:DyaK1cXjs1Kms78%3D (Pubitemid 28239982)
49. T Hasegawa M Matsuzaki-Kobayashi A Takeda, et al. 2006 Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease FEBS Lett 580 2147 2152 16567160 10.1016/j.febslet.2006.03.018 1:CAS:528:DC%2BD28XivV2qtLs%3D
50. FJ Lee F Liu ZB Pristupa, et al. 2001 Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis FASEB J 15 916 926 11292651 10.1096/fj.00-0334com 1:CAS:528:DC%2BD3MXivFOrt7g%3D (Pubitemid 32290778)